Abstract：
OBJECTIVE: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality worldwide. Statins, which are effective in preventing ASCVD, are underused, particularly for primary prevention. This study examined trends in statin use for primary ASCVD prevention from 1999 to 2020, focusing on demographic variations.
METHODS: Utilizing data from the National Health and Nutrition Examination Survey, the present study includes individuals aged 18 years and older who had a greater than 10% risk of ASCVD over 10 years, and excluded patients with existing ASCVD. Subgroup analyses by demographic categories were performed. We calculated the changes in statin usage and used linear and quadratic tests to assess the linear and nonlinear trends in those changes.
RESULTS: A total of 10,037 participants were included. Statin usage increased from 16.16% in 1999 to 36.24% in 2010, and 41.74% in 2020 (quadratic P-value < 0.001). In the 18-44 years age group, statin usage increased from 2.52% in 1999 to 8.14% in 2020 (linear P-value = 0.322), showing no significant linear trend. In the \"never-married\" group, statin usage increased from 19.16% in 1999 to 30.05% in 2020 (linear P-value = 0.256).
CONCLUSIONS: Statin usage has shown a positive trend among populations requiring primary prevention for ASCVD. Currently, health policies are proving effective. However, the overall statin usage rate remains less than 50%. Additionally, young and never-married individuals should also receive special attention regarding statin usage as primary treatment for ASCVD.
METHODS: Utilizing data from the National Health and Nutrition Examination Survey, the present study includes individuals aged 18 years and older who had a greater than 10% risk of ASCVD over 10 years, and excluded patients with existing ASCVD. Subgroup analyses by demographic categories were performed. We calculated the changes in statin usage and used linear and quadratic tests to assess the linear and nonlinear trends in those changes.
RESULTS: A total of 10,037 participants were included. Statin usage increased from 16.16% in 1999 to 36.24% in 2010, and 41.74% in 2020 (quadratic P-value < 0.001). In the 18-44 years age group, statin usage increased from 2.52% in 1999 to 8.14% in 2020 (linear P-value = 0.322), showing no significant linear trend. In the \"never-married\" group, statin usage increased from 19.16% in 1999 to 30.05% in 2020 (linear P-value = 0.256).
CONCLUSIONS: Statin usage has shown a positive trend among populations requiring primary prevention for ASCVD. Currently, health policies are proving effective. However, the overall statin usage rate remains less than 50%. Additionally, young and never-married individuals should also receive special attention regarding statin usage as primary treatment for ASCVD.
摘要：
目的：动脉粥样硬化性心血管疾病（ASCVD）是全球死亡的主要原因。他汀类药物,有效预防ASCVD，未被充分利用，特别是一级预防。这项研究调查了1999年至2020年他汀类药物用于原发性ASCVD预防的趋势，重点是人口统计学差异。
方法：利用国家健康和营养调查的数据，本研究包括18岁及以上的个体，他们在10年内患ASCVD的风险超过10%，并排除存在ASCVD的患者。按人口统计类别进行亚组分析。我们计算了他汀类药物使用的变化，并使用线性和二次检验来评估这些变化的线性和非线性趋势。
结果：共纳入10,037名参与者。他汀类药物的使用率从1999年的16.16%增加到2010年的36.24%和2020年的41.74%（二次P值<0.001）。在18-44岁年龄段，他汀类药物的使用率从1999年的2.52%增加到2020年的8.14%（线性P值=0.322），没有明显的线性趋势。在“从未结婚”小组中，他汀类药物的使用率从1999年的19.16%增加到2020年的30.05%(线性P值=0.256)。
结论：他汀类药物的使用在需要ASCVD一级预防的人群中显示出积极的趋势。目前,卫生政策被证明是有效的。然而,他汀类药物的总体使用率仍低于50%.此外,年轻和未婚人士也应特别注意将他汀类药物作为ASCVD的主要治疗方法.
方法：利用国家健康和营养调查的数据，本研究包括18岁及以上的个体，他们在10年内患ASCVD的风险超过10%，并排除存在ASCVD的患者。按人口统计类别进行亚组分析。我们计算了他汀类药物使用的变化，并使用线性和二次检验来评估这些变化的线性和非线性趋势。
结果：共纳入10,037名参与者。他汀类药物的使用率从1999年的16.16%增加到2010年的36.24%和2020年的41.74%（二次P值<0.001）。在18-44岁年龄段，他汀类药物的使用率从1999年的2.52%增加到2020年的8.14%（线性P值=0.322），没有明显的线性趋势。在“从未结婚”小组中，他汀类药物的使用率从1999年的19.16%增加到2020年的30.05%(线性P值=0.256)。
结论：他汀类药物的使用在需要ASCVD一级预防的人群中显示出积极的趋势。目前,卫生政策被证明是有效的。然而,他汀类药物的总体使用率仍低于50%.此外,年轻和未婚人士也应特别注意将他汀类药物作为ASCVD的主要治疗方法.
